Omecamtiv mecarbil clinical trials
Also written AMG 423 and CK-1827452.
How each study uses omecamtiv mecarbil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the omecamtiv mecarbil studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test omecamtiv mecarbil, phase 3 first.
- Sep 2027Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionPhase 3 · Cytokinetics
Studies
Open first, then newest update. How each study uses omecamtiv mecarbil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionRecruitingPhase 3CytokineticsNCT06736574Written as Omecamtiv Mecarbil (OM)
- Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy AdultsCompletedPhase 1CytokineticsNCT04175808Written as Omecamtiv Mecarbil (OM)
- Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart FailureCompletedPhase 3CytokineticsNCT03759392Written as Omecamtiv Mecarbil
- Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionCompletedPhase 3CytokineticsNCT02929329Written as Omecamtiv Mecarbil
- COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart FailureCompletedPhase 2CytokineticsNCT01786512Written as Omecamtiv Mecarbil Matrix F1 Formulation
- Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal InsufficiencyCompletedPhase 1CytokineticsNCT01737866Written as AMG 423
- Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure PatientsWithdrawnPhase 2CytokineticsNCT01077167Written as Omecamtiv mecarbil
- Omecamtiv Mecarbil Post-trial Access StudyWithdrawnPhase 3CytokineticsNCT04464525Written as Omecamtiv mecarbil
- Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection FractionCompletedPhase 2CytokineticsNCT02695420Written as 25 mg Omecamtiv Mecarbil
- Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese AdultsCompletedPhase 1CytokineticsNCT02601001Written as Omecamtiv mecarbil
- Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)CompletedPhase 2CytokineticsNCT01300013Written as Omecamtiv mecarbil
- A Study of CK-1827452 Infusion in Stable Heart FailureCompletedPhase 2CytokineticsNCT00624442Written as CK-1827452
- Phase II Study of the Effect of CK-1827452 Injection on Myocardial EfficiencyTerminatedPhase 2CytokineticsNCT00748579Written as CK-1827452
- PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and AnginaCompletedPhase 2CytokineticsNCT00682565Written as CK-1827452 24mg and 6 mg iv infusion
- A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy VolunteersCompletedPhase 1CytokineticsNCT01380223Written as omecamtiv mecarbil
- Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart FailureCompletedPhase 2CytokineticsNCT00941681Written as CK-1827452
Codes
What other systems call omecamtiv mecarbil · ClinicalTrials.gg INT005574
- MeSH (NLM) C547293omecamtiv mecarbilOne source NLM
- UNII (FDA) 2M19539ERKOMECAMTIV MECARBILConfirmed FDA, NLM, Wikidata
- Wikidata Q7089956omecamtiv mecarbilConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166579Omecamtiv MecarbilOne source FDA
- DrugBank DB11816One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C547293 | omecamtiv mecarbil | One source NLM |
| UNII (FDA) | 2M19539ERK | OMECAMTIV MECARBIL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7089956 | omecamtiv mecarbil | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166579 | Omecamtiv Mecarbil | One source FDA |
| DrugBank | DB11816 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.